The following transcript has been edited for clarity:

Hey everybody, Christine Funke, MD, here at AAO. I am a glaucoma and cataract surgeon out of Phoenix, Arizona, at Barnet Dulaney Perkins Eye Center, and lucky enough to be here to talk about interventional glaucoma.

AAO is such a great platform to really discuss the changes in glaucoma. Interventional glaucoma is becoming a huge new burgeoning area of how we're wanting to treat our glaucoma patients. Mainly what I'm focusing on is talking about what MIGS are available, what lasers are available, and how to really integrate them into the practice, especially when we're talking about patients who are coming to us early—so young disease, young glaucoma. We don't want to just pepper them with drops, and forget that interventional glaucoma works best if we’d pop in there with it at the beginning of disease. Because at the beginning of disease, there are a lot of modifiable factors when we’re talking about trabecular meshwork and downstream. So my big discussion here today is, remember that when somebody is coming in to you early, that’s really a great time to talk about SLT, talk about minimally invasive glaucoma surgery, because that's when you're going to find success by using those different tools. I think we're just benefiting our patients long term by slowing down the progression of their disease and obviously it’s slowing down field loss, which is really the goal for all of us. GP